Hemostemix Inc., a clinical-stage biotechnology company, is making headlines today with a bold new initiative aimed at expanding access to its autologous stem cell therapy, VesCell™ (ACP-01), across Florida under the state’s compassionate-use framework.

---

What’s New Today?

“Boots on the ground” initiative launched in Florida
Hemostemix has officially rolled out a face-to-face sales and outreach program in Miami, Naples, and Tampa. Spearheaded by CEO Thomas Smeenk and CCO Croom Lawrence, the team is engaging directly with podiatrists, cardiologists, vascular surgeons, and former Phase II trial investigators to build awareness and facilitate adoption of VesCell™ in clinics statewide.

---

Why It Matters

1. Regulatory Pathway Utilization
Florida’s SB 1768 right-to-try law allows Hemostemix to offer VesCell™ to patients with life-threatening or severely debilitating conditions who have exhausted standard-of-care options. This innovative approach enables patients to access cutting-edge treatments while Hemostemix gathers real-world evidence to support future FDA submissions.

2. Substantive Clinical Evidence
By August 2025, Hemostemix has treated 498 patients, completed seven clinical studies involving 318 subjects, and published findings across 11 peer-reviewed journals—all reinforcing VesCell™’s safety and efficacy in treating conditions like CLTI, angina, and various cardiomyopathies.
Clinical highlights include dramatic ulcer healing (from 1.46 cm² down to 0.48 mm² in three months, p = 0.01), improved cardiac function, and enhanced patient comfort and mobility.

3. Building Clinical Partnerships
Hemostemix’s engagement model emphasizes relationship-building: they’re not just promoting a treatment—they’re collaborating with clinicians who are familiar with ACP-01 from the trials. The aim is to foster trust, streamline adoption, and ensure rigorous data collection for later regulatory interaction.

---

Broader Context: Strategy Meets Execution

• Funding and Growth
  Hemostemix has secured multiple rounds of financing, including a recent private placement, giving the company resources to drive commercialization in Florida and prepare for eventual FDA interaction.
• Dual Purpose Rollout
  The Florida initiative both generates revenue through compassionate-use treatments and builds a robust evidence base for regulators—reinforcing Hemostemix’s long-term strategy.

---

Suggested Headlines to Raise Awareness

• Hemostemix Brings Stem Cell Therapy to Florida: “Boots on the Ground” Initiative Takes VesCell™ Directly to Clinics
• Autologous Stem Cell Access in Action: Hemostemix Engages Florida Clinicians to Transform Care for No-Option Patients
• From Trials to Treatment: Hemostemix’s On-the-Ground Strategy in Florida Sets Stage for Broader Approval

---

Why This Announcement Matters — In Short

• Patients: Offers new hope to individuals with severe, otherwise untreatable conditions.
• Clinicians: Provides direct access to a promising therapy and support for implementation.
• Investors: Demonstrates tactical commercialization with regulatory foresight and clinical validation.
• Industry: Signals a novel model for balancing compassionate use with evidence generation in biomedicine.

---

Sources

• Hemostemix’s Boots on the Ground in Florida

---

Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.

The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.

Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.

EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.

By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.

Welcome to the first of a series of video clips from our CEO.

The purposes of these clips are to give you:
✅In Depth Look at Snow Lake Energy
✅Our Strategy
✅Our Critical Minerals Projects
🚨 Global Events that will Help Shape the Future Of Snow Lake

NASDAQ: $LITM pic.twitter.com/WbZ1IxXROp

— Snow Lake Energy (@SnowLakeEnergy) August 21, 2025

Snow Lake Resources Ltd., operating as Snow Lake Energy (NASDAQ: LITM), is stepping up its investor engagement with a new video series on X, showcasing its uranium exploration projects and expanding role in the global clean energy transition.

The Canadian-based critical minerals explorer is using social media to pull back the curtain on its operations, giving investors an inside look at how it’s aligning with U.S. energy security priorities and tapping into surging demand for nuclear power to fuel AI-driven infrastructure.

---

A Strategic Pivot Toward Uranium

Snow Lake Energy has undergone a major pivot, shifting focus from lithium toward uranium — a move driven by tightening global energy markets and nuclear’s rising profile as a clean, base-load power source.

• Pine Ridge Uranium Project (Wyoming): A 50/50 joint venture with Global Uranium & Enrichment Limited (GUE), strategically located in the Powder River Basin near Cameco’s Smith Ranch Mill, which processes up to 5.5 million pounds of U3O8 annually. Pine Ridge is advancing as an in-situ recovery (ISR) project with an aggressive 125,000-foot drill program set for 2025.
• Engo Valley Project (Namibia): Early results are promising, and Phase 2 drilling (7,500 meters) is underway to build out a stronger resource model.

This uranium focus comes as the U.S. government accelerates domestic nuclear investment through four Nuclear Executive Orders signed in May 2025, aimed at rapidly expanding nuclear deployment to meet AI-related energy needs.

---

Investor Outreach Through Multimedia

The X video series is part of Snow Lake’s strategy to make complex exploration updates digestible and exciting for investors. The clips likely feature:

• On-site footage from drill programs
• Expert commentary from leadership
• Visual data highlighting resource potential

By turning technical progress into compelling stories, Snow Lake is aiming to build momentum with both institutional and retail investors. CEO Frank Wheatley has repeatedly emphasized the company’s commitment to transparency and engagement, with the video rollout complementing frequent press releases and appearances at investor conferences such as ThinkEquity 2024.

Notably, Snow Lake has also partnered with Exodys Energy to create a new nuclear reactor development company focused on small modular reactors (SMRs), further solidifying its positioning in the clean energy sector.

Welcome to the 2nd video of a series of video clips from our CEO.

Discuss is our two pronged strategy:
1️⃣ Expand our footprint across the nuclear fuel cycle…

2️⃣ Expand both our portfolio of and investments in North America critical mineral projects

NASDAQ: $LITM pic.twitter.com/jAdowk2w1c

— Snow Lake Energy (@SnowLakeEnergy) August 25, 2025

---

Market Momentum and Investor Sentiment

The timing is crucial. Uranium prices have surged amid geopolitical pressures and global decarbonization policies, sparking renewed investor interest. Snow Lake’s own shares spiked more than 70% in December 2024 following a $15 million public offering at $0.80 per share to fund exploration.

Still, analysts remain cautious. Current ratings lean “hold,” citing negative returns on assets (-7.4%) and equity (-14.5%), even as sentiment around uranium builds. Snow Lake’s video series may be designed to counterbalance these headwinds by emphasizing long-term potential and policy tailwinds, especially with the U.S. targeting a quadrupling of nuclear power by 2050.

---

Outlook: Riding the Clean Energy Wave

With a market cap near $30.5 million (May 2025) and shares trading at $3.94, Snow Lake remains a speculative but ambitious small-cap. Its success depends on proving out Pine Ridge and Engo Valley while keeping investors engaged with visible progress.

By leaning on multimedia storytelling, Snow Lake is turning its corporate updates into a broader clean-energy narrative — one that investors tracking nuclear, AI power demand, and critical minerals will find increasingly hard to ignore.

As one X user recently put it, “Momentum is exploding for assets tied to the energy transition.” Snow Lake is clearly betting it can ride that wave.

👉 For more details, visit www.snowlakeenergy.com or follow @SnowLakeEnergy on X for the latest videos and corporate news.

---

Disclaimer

Lusso’s News, LLC (“we,” “our,” or “the Company”) has been compensated fifteen thousand U.S. dollars (USD $15,000) by a third party for investor awareness and media coverage related to Snow Lake Resources Ltd. (NASDAQ: LITM). This compensation is for a six-month period beginning June 2025 and ending December 2025.

The content provided by Lusso’s News, LLC, including but not limited to articles, videos, social media posts, and other media, is intended for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. We are not registered as a broker-dealer, investment advisor, or in any other capacity with the U.S. Securities and Exchange Commission (SEC) or any state securities authority.

This material may contain forward-looking statements, including projections, forecasts, estimates, and other information that is predictive in nature. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of Snow Lake Resources Ltd. or Lusso’s News, LLC, that could cause actual results to differ materially from those anticipated. Readers should not place undue reliance on such statements.

Investing in securities, particularly micro-cap and small-cap stocks, involves substantial risk, including the potential for total loss of principal. Always conduct your own independent research and consult with a licensed financial advisor before making any investment decisions.

Lusso’s News, LLC assumes no responsibility or liability for any investment decisions made based on the information we provide. By viewing our content, you acknowledge and agree to these terms.

On July 1, 2025, Florida enacted Senate Bill 1768, a landmark law allowing physicians to offer certain autologous stem cell therapies that are not yet FDA-approved, provided patients give informed consent and the procedures are conducted by licensed professionals.

This regulatory shift creates an immediate opportunity for Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF), a Canadian regenerative medicine company specializing in VesCell/ACP-01, a therapy designed to restore blood flow and promote healing in patients suffering from severe ischemia.

Why This Matters for Hemostemix

Hemostemix has already treated over 498 patients with ACP-01, showing trial results that include smaller ulcer sizes, improved circulation, and reduced amputation rates. With Florida’s new legal framework, the company can now commercialize VesCell in the Sunshine State before FDA approval—potentially accelerating both adoption and revenue. First treatments in Florida are targeted for late 2025, and Hemostemix projects $22.5 million in sales for 2026.

Learning from Other Biotech Breakouts

The biotech sector has a history of companies making exponential gains when innovation meets the right market conditions:

• Exact Sciences rose from ~$2 in 2013 to over $130 at its peak on the success of its Cologuard cancer test.
• Moderna was a relatively unknown small-cap before its mRNA platform propelled its COVID-19 vaccine to global use, driving shares from around $18 to nearly $500.
• Vertex Pharmaceuticals climbed more than 1,000% over a decade by pioneering treatments for cystic fibrosis.
• Regeneron surged over 600% on the blockbuster performance of its eye drug Eylea.
• Novavax went from under $5 to over $300 during the race to produce a COVID-19 vaccine.

Each of these cases involved a scientific breakthrough meeting favorable timing—whether regulatory changes, urgent public health needs, or key clinical results.

The Road Ahead

It’s important to note that VesCell remains investigational, and investment in early-stage biotech carries significant risk. Florida’s new law does not imply FDA approval; rather, it creates a pathway for patients and physicians to access therapies under specific conditions.

For Hemostemix, this legal shift may represent a pivotal moment—much like other inflection points that helped propel biotech companies from obscurity to the forefront of their fields. Whether the company follows that trajectory will depend on clinical performance, market uptake, and investor confidence in the years ahead.

---

Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.

The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.

Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.

EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.

By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.